NV-ESI-GROUP
7.1.2020 08:02:14 CET | Business Wire | Press release
ESI Group (Paris:ESI), leading innovator in Virtual Prototyping software and services for manufacturing industries, helped Farasis Energy, a Chinese-American battery provider, win in record-breaking time, a call for tenders made by a premium German automotive OEM. Thanks to ESI’s expertise, the reliability of the virtual prototype of the new Farasis battery model was decisive in a “zero real prototype” procedure, stipulating the elimination of any physical prototype.
The move of the automotive industry toward electrification is seemingly unstoppable. Manufacturers are announcing aggressive plans for Electric Vehicle (EV) production, and the International Energy Agency says the number of EVs will grow from 3 to 125 million by 2030. So, it’s no wonder that new players are entering the market, breaking the traditional rules of product design – new players like lithium-ion battery maker Farasis Energy. Looking to collect wins in this fast-growing market, the team at Farasis relied on ESI’s expertise to prove to a major German car maker that they were the best supplier – based solely on a virtual prototype. This collaboration around ESI’s Virtual Performance Solution (VPS) allowed to virtualize and secure the behavior of the battery in vibration or vehicle crash situations.
Dr. Matt Klein, Advanced R&D Director at Farasis Energy, emphasized the key role ESI played in this project: “Half-way through the bidding process, the manufacturer actually decided to remove the physical prototype step – they would make their decision based on the virtual prototype. In just 8 months, we went from limited Virtual Prototyping capability to winning those bids. The head of the whole program conducting the bidding process went out of his way to tell us that the mechanical simulation was an instrumental part in helping us get the design approved. We could not have done that without ESI. Our partnership with ESI is truly strategic in bringing our simulation capabilities to a global leading standard.”
Two fundamental elements differentiated ESI’s VPS in this project:
- The reliability of the results, eliminating the need for a real prototype verification, as a result of the consideration of complex physical phenomenon inside the battery.
- The integration level of different virtual vibration and crash tests in one solution, allowing iteration loops and quick decisions.
Farasis relied on ESI’s proven knowledge of the automotive industry and ability to provide real results, virtually, thanks to virtual prototyping. The capability to build a global model, covering several engineering disciplines, led to a highly efficient workflow and ultimately a cost-effective solution for Farasis.
Since their win, Farasis has opened a new factory on-site in Germany, dedicated to the research & development of their batteries for the German car maker. ESI is now putting in place a platform for Farasis’ international team of simulation engineers, one that is fully automated and customized to their way of working. Thanks to this Platform, the Farasis team will work together – regardless of what continent they are on – with great efficiency and transparency, on common Virtual Prototyping models. And what began as a bi-lateral partnership has quickly evolved into an ecosystem comprised of three major players – Farasis, ESI Group, and the automotive manufacturer – all hungry to tap into the EV market.
About Farasis
Farasis Energy, Inc. created in California in 2002 is a company specialized in the conception and distribution of batteries. Present in China (headquarters), in the Silicon Valley (R&D center), and in Europe, the Group is one of the world leaders in his sector. Farasis’ ambition is to position itself as a pivot to better meet the challenges of its industrial clients: saving time to market and the costs of production while maintaining a high level of reliability and safety.
ESI and Farasis will jointly showcase their expertise and partnership at the CES 2020 in Las Vegas. Meet them in ESI Booth: LVCC, Automotive Section - North Hall, booth #9020
About ESI Group
ESI Group is a leading innovator in Virtual Prototyping software and services. Specialist in material physics, ESI has developed a unique proficiency in helping industrial manufacturers replace physical prototypes by virtual prototypes, allowing them to virtually manufacture, assemble, test and pre-certify their future products. Coupled with the latest technologies, Virtual Prototyping is now anchored in the wider concept of the Product Performance Lifecycle™, which addresses the operational performance of a product during its entire lifecycle, from launch to disposal. The creation of a Hybrid Twin™, leveraging simulation, physics and data analytics, enables manufacturers to deliver smarter and connected products, to predict product performance and to anticipate maintenance needs.
ESI is a French company listed in compartment B of NYSE Euronext Paris. Present in more than 40 countries, and addressing every major industrial sector, ESI Group employs about 1200 high-level specialists around the world and reported annual sales of €139 million in 2018. For more information, please visit www.esi-group.com .
Follow ESI
LinkedIn
Facebook
Twitter
YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005895/en/
Contact:
ESI Group Shan Florence Barré press@esi-group.com +33 1 49 78 28 28
Lola Gozlan lola.gozlan@shan.fr +33 6 24 76 83 40
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom